Potential Role of NK Cells in the Induction of Immune Responses: Implications for NK Cell–Based Immunotherapy for Cancers and Viral Infections

REFERENCES

• Kiessling R., Klein E., Pross H., Wigzell H. “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur. J. Immunol. 1975; 5: 112–117
   PubMed Web of Science ®Google Scholar
• Herberman R. B., Nunn M. E., Lavrin D. H. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity and specificity. Int. J. Cancer 1975; 16: 216–229
   PubMed Web of Science ®Google Scholar
• Kärre K., Ljunggren H. G., Piontek G., Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319: 675–678
   PubMed Web of Science ®Google Scholar
• Yokoyama W. M., Seaman W. E. The Ly-49 and NKR-P1 gene families encoding lectin-like receptors on natural killer cells: The NK gene complex. Annu. Rev. Immunol. 1993; 11: 613–635
   PubMed Web of Science ®Google Scholar
• Lanier L. L. NK cell receptors. Annu. Rev. Immunol. 1998; 16: 359–393
   PubMed Web of Science ®Google Scholar
• Mandelboim O., Lieberman N., Lev M., Paul L., Arnon T. I., Bushkin Y., Davis D. M., Strominger J. L., Yewdell J. W., Porgador A. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001; 409: 1055–1060
   PubMed Web of Science ®Google Scholar
• Arnon T. I., Lev M., Katz G., Chernobrov Y., Porgador A., Mandelboim O. Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur. J. Immunol. 2001; 31: 2680–2689
   PubMed Web of Science ®Google Scholar
• Arnon T. I., Achdout H., Levi O., Markel G., Saleh N., Katz G., Gazit R., Gonen-Gross T., Hanna J., Nahari E., Porgador A., Honigman A., Plachter B., Mevorach D., Wolf D. G., Mandelboim O. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat. Immunol. 2005; 6: 515–523
   PubMed Web of Science ®Google Scholar
• Martin M. P., Gao X., Lee J. H., Nelson G. W., Detels R., Goedert J. J., Buchbinder S., Hoots K., Vlahov D., Trowsdale J., Wilson M., O'Brien S. J., Carrington M. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 2002; 31: 429–434
   PubMed Web of Science ®Google Scholar
• Martin M. P., Gao X., Yamada E., Martin J. N., Pereyra F., Colombo S., Brown E. E., Shupert W. L., Phair J., Goedert J. J., Buchbinder S., Kirk G. D., Telenti A., Connors M., O'Brien S. J., Walker B. D., Parham P., Deeks S. G., McVicar D. W., Carrington M. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat. Genet. 2007; 39: 733–740
   PubMed Web of Science ®Google Scholar
• Passweg J. R., Huard B., Tiercy J. M., Roosnek E. HLA and KIR polymorphisms affect NK-cell anti-tumor activity. Trends Immunol. 2007; 28: 437–441
   PubMed Web of Science ®Google Scholar
• Ferrone S., Marincola F. M. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional signincance and clinical relevance. Immunol. Today 1995; 16: 487–494
   PubMedGoogle Scholar
• Tsukahara T., Kawaguchi S., Torigoe T., Asanuma H., Nakazawa E., Shimozawa K., Nabeta Y., Kimura S., Kaya M., Nagoya S., Wada T., Yamashita T., Sato N. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci. 2006; 97: 1374–1380
   PubMed Web of Science ®Google Scholar
• Kitamura H., Honma I., Torigoe T., Asanuma H., Sato N., Tsukamoto T. Down-regulation of HLA class I antigens is independent prognostic factor for clear cell renal cell carcinoma. J. Urol. 2007; 177: 1269–1272
   PubMedGoogle Scholar
• Bonaparte M. I., Barker E. Inability of natural killer cells to destroy autologous HIV-infected T lymphocytes. AIDS 2003; 17: 487–494
   PubMedGoogle Scholar
• Bonaparte M. I., Barker E. Killing of human immunodeficiency virus-infected primary T-cell blasts by autologous natural killer cells is dependent on the ability of the virus to alter the expression of major histocompatibility complex class I molecules. Blood 2004; 104: 2087–2094
   PubMedGoogle Scholar
• Ward J. P., Bonaparte M. I., Barker E. HLA-C and HLA-E reduce antibody-dependent natural killer cell-mediated cytotoxicity of HIV-infected primary T cell blasts. AIDS 2004; 18: 1769–1779
   PubMedGoogle Scholar
• Cohen G. B., Gandhi R. T., Davis D. M., Mandelboim O., Chen B. K., Strominger J. L., Baltimore D. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999; 10: 661–671
   PubMed Web of Science ®Google Scholar
• Trinchieri G., Valiante N. Receptors for the Fc fragment of IgG on natural killer cells. Nature Immunol. 1993; 12: 218–234
   Google Scholar
• Roda J. M., Parihar R., Magro C., Nuovo G. J., Tridandapani S., Carson W. E. III, Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Cancer Res. 2006; 66: 517–526
   PubMed Web of Science ®Google Scholar
• Clynes R. A., Towers T. L., Presta L. G., Ravetch J. V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 2000; 6: 443–446
   PubMed Web of Science ®Google Scholar
• Sampson J. H., Crotty L. E., Lee S., Archer G. E., Ashley D. M., Wikstrand C. J., Hale L. P., Small C., Dranoff G., Friedman A. H., Friedman H. S., Bigner D. D. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 7503–7508
   PubMed Web of Science ®Google Scholar
• Ahmad A., Morisset R., Thomas R., Menezes J. Evidence for a defect of antibody-dependent cellular cytotoxic (ADCC) effector function and anti-HIV gp120/41-specific ADCC-mediating antibody titres in HIV-infected individuals. J. Acquir. Immune. Defic. Syndr. 1994; 7: 428–437
   PubMedGoogle Scholar
• Gupta N., Arthos J., Khazanie P., Steenbeke T. D., Censoplano N. M., Chung E. A., Cruz C. C., Chaikin M. A., Daucher M., Kottilil S., Mavilio D., Schuck P., Sun P. D., Rabin R. L., Radaev S., van Ryk D., Cicala C., Fauci A. S. Targeted lysis of HIV-infected cells by natural killer cells armed and triggered by a recombinant immunoglobulin fusion protein: implications for immunotherapy. Virology 2005; 332: 491–497
   PubMedGoogle Scholar
• Degli-Esposti M. A., Smyth M. J. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat. Rev. Immunol. 2005; 5: 112–124
   PubMed Web of Science ®Google Scholar
• Fernandez N. C., Lozier A., Flament C., Ricciardi-Castagnoli P., Bellet D., Suter M., Perricaudet M., Tursz T., Maraskovsky E., Zitvogel L. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat. Med. 1999; 5: 405–411
   PubMed Web of Science ®Google Scholar
• Ferlazzo G., Pack M., Thomas D., Paludan C., Schmid D., Strowig T., Bougras G., Muller W. A., Moretta L., Münz C. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc. Natl. Acad. Sci. U. S. A. 2004; 101: 16606–16611
   PubMed Web of Science ®Google Scholar
• Granucci F., Zanoni I., Pavelka N., van Dommelen S. L. H., Andoniou C. E., Belardelli F., Esposti M. A. D., Ricciardi-Castagnoli P. A contribution of mouse dendritic cell-derived IL-2 for NK cell activation. J. Exp. Med. 2004; 200: 287–295
   PubMed Web of Science ®Google Scholar
• Cooper M. A., Fehniger T. A., Fuchs A., Colonna M., Caligiuri M. A. NK cell and DC interactions. Trends Immunol. 2004; 25: 47–52
   PubMed Web of Science ®Google Scholar
• Robertson M. J. Role of chemokines in the biology of natural killer cells. J. Leukoc. Biol. 2002; 71: 173–183
   PubMed Web of Science ®Google Scholar
• Roda J. M., Parihar R., Magro C., Nuovo G. J., Tridandapani S., Carson W. E. III, Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Cancer Res. 2006; 66: 517–526
   PubMed Web of Science ®Google Scholar
• Mavilio D., Lombardo G., Kinter A., Fogli M., La Sala A., Ortolano S., Farschi A., Follmann D., Gregg R., Kovacs C., Marcenaro E., Pende D., Moretta A., Fauci A. S. Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. J. Exp. Med. 2006; 203: 2339–2350
   PubMed Web of Science ®Google Scholar
• Vitale M., Chiesa M. D., Carlomagno S., Pende D., Aricò M., Moretta L., Moretta A. NK-dependent DC maturation is mediated by TNFα and IFNγ released upon engagement of the NKp30 triggering receptor. Blood 2005; 106: 566–571
   PubMed Web of Science ®Google Scholar
• Mavilio D., Benjamin J., Daucher M., Lombardo G., Kottilil S., Planta M. A., Marcenaro E., Bottino C., Moretta L., Moretta A., Fauci A. S. Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 15011–15016
   PubMed Web of Science ®Google Scholar
• Cooper M. A., Fehniger T. A., Caligiuri M. A. The biology of human natural killer-cell subsets. Trends Immunol. 2001; 22: 633–640
   PubMed Web of Science ®Google Scholar
• Dewan M. Z., Terunuma H., Takada M., Tanaka Y., Abe H., Sata T., Toi M., Yamamoto N. Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo. Breast Cancer Res. Treat. 2007; 104: 267–275
   PubMedGoogle Scholar
• Dewan M. Z., Terunuma H., Toi M., Tanaka Y., Katano H., Deng X., Abe H., Nakasone T., Mori N., Sata T., Yamamoto N. Potential role of natural killer cells in controlling growth and infiltration of AIDS-associated primary effusion lymphoma cells. Cancer Sci. 2006; 97: 1381–1387
   PubMedGoogle Scholar
• Imai K., Matsuyama S., Miyake S., Suga K., Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000; 356: 1795–1799
   PubMed Web of Science ®Google Scholar
• Bobek V., Boubelik M., Fišerová A., L'uptovcová M., Vannucci L., Kacprzak G., Kolodzej J., Majewski A. M., Hoffman R. M. Anticoagulant drugs increase natural killer cell activity in lung cancer. Lung Cancer 2005; 47: 215–223
   PubMed Web of Science ®Google Scholar
• Whiteside T. L., Herberman R. B. Role of human natural killer cells in health and disease. Clin. Diagn. Lab. Immunol. 1994; 1: 125–133
   PubMedGoogle Scholar
• Ishigami S., Natsugoe S., Tokuda K., Nakajo A., Che X., Iwashige H., Aridome K., Hokita S., Aikou T. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000; 88: 577–583
   PubMed Web of Science ®Google Scholar
• Takanami I., Takeuchi K., Giga M. The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma. J. Thorac. Cardiovasc. Surg. 2001; 121: 1058–1063
   Google Scholar
• Coca S., Perez-Piqueras J., Martinez D., Colmenarejo A., Saez M. A., Vallejo C., Martos J. A., Moreno M. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997; 79: 2320–2328
   PubMed Web of Science ®Google Scholar
• Escudier B., Farace F., Angevin E., Charpentier F., Nitenberg G., Triebel F., Hercend T. Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL-2. Eur. J. Cancer 1994; 30A: 1078–1083
   PubMedGoogle Scholar
• Ishikawa E., Tsuboi K., Saijo K., Harada H., Takano S., Nose T., Ohno T. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res. 2004; 24: 1861–1871
   PubMed Web of Science ®Google Scholar
• Burns L. J., Weisdorf D. J., DeFor T. E., Vesole D. H., Repka T. L., Blazar B. R., Burger S. R., Panoskaltsis-Mortari A., Keever-Taylor C. A., Zhang M.-J., Miller J. S. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: A phase I/II trial. Bone Marrow Transplant. 200; 32: 177–186
   Google Scholar
• Brand J.-M., Meller B., von Hof K., Luhm J., Bähre M., Kirchner H., Frohn C. Kinetics and organ distribution of allogeneic natural killer lymphocytes transfused into patients suffering from renal cell carcinoma. Stem Cells Development 2004; 13: 307–314
   PubMedGoogle Scholar
• Gattinoni L., Powell D. J., Jr., Rosenberg S. A., Restifo N. P. Adoptive immunotherapy for cancer: Building on success. Nat. Rev. Immunol. 2006; 6: 383–393
   PubMed Web of Science ®Google Scholar
• Smyth M. J., Teng M. W., Swann J., Kyparissoudis K., Godfrey D. I., Hayakawa Y. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J. Immunol. 2006; 176: 1582–1587
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F., Ménard C., Terme M., Flament C., Taieb J., Chaput N., Puig P. E., Novault S., Escudier B., Vivier E., Lecesne A., Robert C., Blay J.-Y., Bernard J., Caillat-Zucman S., Freitas A., Tursz T., Wagner-Ballon O., Capron C., Vainchencker W., Martin F., Zitvogel L. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J. Exp. Med. 2005; 202: 1075–1085
   PubMed Web of Science ®Google Scholar
• Kitchens W. H., Uehara S., Chase C. M., Colvin R. B., Russell P. S., Madsen J. C. The changing role of natural killer cells in solid organ rejection and tolerance. Transplantation 2006; 81: 811–817
   PubMed Web of Science ®Google Scholar
• Terunuma H., Wada A., Deng X., Yasuma Y., Onishi T., Toki A., Abe H. Mild hyperthermia modulates the relative frequency of lymphocyte cell subpopulations: an increase in a cytolytic NK cell subset and a decrease in a regulatory T cell subset. Thermal Medicine 2007; 23: 41–47
   Google Scholar
• Goldfarb R. H., Ohashi M., Brunson K. W., Kirii Y., Kotera Y., Basse P. H., Kitson R. P. Augmentation of IL-2 activated natural killer cell adoptive immunotherapy with cyclophosphamide. Anticancer Res. 1998; 18: 1441–1446
   PubMedGoogle Scholar
• Okita R., Yamaguchi Y., Emi A., Matsuura K., Toga T. Enhancement of lymphokine-activated killer cell induction using anti-CD25 and anti-CTLA-4 monoclonal antibodies. Oncol. Rep. 2007; 17: 1429–1435
   PubMedGoogle Scholar
• Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W. D., Tosti A., Posati S., Rogaia D., Frassoni F., Aversa F., Martelli M. F., Velardi A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097–2100
   PubMed Web of Science ®Google Scholar
• Miller J. S., Soignier Y., Panoskaltsis-Mortari A., McNearney S. A., Yun G. H., Fautsch S. K., McKenna D., Le C., Defor T. E., Burns L. J., Orchard P. J., Blazar B. R., Wagner J. E., Slungaard A., Weisdorf D. J., Okazaki I. J., McGlave P. B. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051–3057
   PubMed Web of Science ®Google Scholar
• Igarashi T., Wynberg J., Srinivasan R., Becknell B., McCoy J. P., Jr., Takahashi Y., Suffredini D. A., Linehan W. M., Caligiuri M. A., Childs R. W. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 2004; 104: 170–177
   PubMed Web of Science ®Google Scholar
• Figdor C. D., de Vries I. J., Lesterhuis W. J., Melief C. J. Dendritic cell immunotherapy: mapping the way. Nat. Med. 2004; 10: 475–480
   PubMed Web of Science ®Google Scholar
• Feenstra M., Veltkamp M., Van Kuik J., Wiertsema S., Slootweg P., Van den Tweel J., de Weger R., Tilanus M. HLA class I expression and chromosomal deletions at 6p and 15q in head and neck sequamous cell carcinomas. Tissue Antigens 1999; 54: 235–245
   PubMedGoogle Scholar
• Maleno I., López-Nevot M. A., Cabrera T., Salinero J., Garrido F. Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol. Immunother. 2002; 51: 389–396
   PubMed Web of Science ®Google Scholar
• Madjd Z., Spendlove I., Pinder S. E., Ellis I. O., Durrant L. G. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int. J. Cancer 2005; 117: 248–255
   PubMed Web of Science ®Google Scholar
• Korkolopoulou P., Kaklamanis L., Pezzella F., Harris A. L., Gatter K. C. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br. J. Cancer 1996; 73: 148–153
   PubMed Web of Science ®Google Scholar
• Kutomi G., Tamura Y., Torigoe T., Sato N. Effective immunotherapy by HSP-cancer peptide complex and immune escape of HLA class I antigen down regulation. Igaku No Ayumi (Japanese) 2007; 221: 627–630
   Google Scholar
• Sandel M. H., Speetjens F. M., Menon A. G., Albertsson P. A., Basse P. H., Hokland M., Nagelkerke J. F., Tollenaar R. A. E. M., van de Velde C. J. H., Kuppen P. J. K. Natural killer cells infiltrating colorectal cancer and MHC class I expression. Molecular Immunol. 2005; 42: 541–546
   PubMed Web of Science ®Google Scholar
• Watson N. F. S., Ramage J. M., Madjd Z., Spendlove I., Ellis I. O., Scholefield J. H., Durrant L. G. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int. J. Cancer 2006; 118: 6–10
   PubMed Web of Science ®Google Scholar
• Romero J. M., Jiménez P., Cabrera T., Cózar J. M., Pedrinaci S., Tallada M., Garrido F., Ruiz-Cabello F. Coordinated downregulation of the antigen presentation machinery and HLA class I/β 2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. Int. J. Cancer 2005; 113: 605–610
   PubMed Web of Science ®Google Scholar
• Kitamura H., Torigoe T., Asanuma H., Honma I., Sato N., Tsukamoto T. Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition. J. Urol. 2007; 178: 692–696
   PubMedGoogle Scholar
• Koopman L. A., Corver W. E., van der Slik A. R., Giphart M. J., Fleuren G. J. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J. Exp. Med. 2000; 191: 961–975
   PubMed Web of Science ®Google Scholar
• Vitale M., Pelusi G., Taroni B., Gobbi G., Micheloni C., Rezzani R., Donato F., Wang X., Ferrone S. HLA class I antigen down-regulation in primary ovary carcinoma lesions: Association with disease stage. Clin. Cancer Res. 2005; 11: 67–72
   PubMed Web of Science ®Google Scholar